Radiation Therapy

Patient Story

"When my doctor said 'radiation,' I pictured something out of a science fiction movie. I imagined glowing green, burning skin, and being locked in a room. The reality? I drove myself to treatment every morning, lay on a table for about 15 minutes, felt absolutely nothing, and drove to work afterward. Five treatments over two weeks, and I was done. My biggest side effect was needing to urinate a little more often for a few weeks. Looking back, the anxiety before treatment was worse than the treatment itself."

— Robert, 64, favorable intermediate-risk prostate cancer, treated with SBRT

Part 1: What Is Radiation Therapy?

Radiation therapy uses high-energy beams to damage the DNA inside cancer cells. When DNA is damaged beyond repair, the cell dies. While radiation affects both cancer cells and normal cells, cancer cells are generally worse at repairing DNA damage — this is the fundamental reason radiation therapy works.

Think of it this way: both cancer cells and normal cells get hit by radiation, but normal cells have better "repair crews." Cancer cells, because of their genetic abnormalities, often cannot fix the damage and die. Normal cells repair themselves and recover. This difference — called the therapeutic window — is what allows radiation to kill cancer while sparing most of the surrounding healthy tissue.

Radiation therapy is a local treatment. Unlike chemotherapy, which travels through the entire body, radiation treats only the area where it is aimed. This means side effects are limited to the treated region.

A brief history: Radiation has been used to treat cancer for over 100 years. Early treatments were imprecise and caused significant side effects. Over the past two decades, revolutionary advances in imaging, computer planning, and delivery technology have transformed radiation therapy into one of the most precise treatments in all of medicine. Modern radiation can target the prostate with millimeter accuracy while minimizing dose to the rectum, bladder, and other nearby structures.

Key concept — radiation therapy is curative. For most men with localized prostate cancer, radiation therapy is a first-line curative treatment with outcomes equivalent to surgery. It is NOT a "last resort" or a lesser option.¹ ²

📊 Illustration 10.1 — How radiation damages cancer cell DNA (simplified diagram showing X-ray beam → DNA double-strand break → cancer cell death vs. normal cell repair)

Part 2: The Contexts of Radiation Therapy

Radiation therapy is used in several different situations in prostate cancer. Understanding these contexts is important because the goals, doses, and treatment areas are different for each:

• Definitive radiation: Radiation as the primary (first) treatment for prostate cancer, with the goal of curing the cancer. This is equivalent to surgery as a curative option.
• Salvage radiation: Radiation given after surgery when PSA rises, indicating possible cancer recurrence. The goal is still cure. Most effective when given early, at low PSA levels.
• Adjuvant radiation: Radiation given shortly after surgery based on adverse pathology findings (positive margins, extraprostatic extension), before PSA rises. Recent trials have shown that early salvage radiation (waiting for PSA to rise) is preferred over adjuvant radiation (treating immediately), as it avoids overtreatment without compromising outcomes.
• Palliative radiation: Radiation given to relieve symptoms — such as bone pain from metastases, spinal cord compression, or bleeding — rather than to cure. Palliative radiation can dramatically improve quality of life.

Each of these contexts is discussed in detail in Chapters 12 and 13. This chapter focuses on the technology, process, and side effects that apply across all contexts.

📊 Illustration 10.17 — Four contexts of radiation therapy (simple 4-box diagram with icons)

Part 3: The Radiation Therapy Team

Radiation therapy involves a specialized team of professionals who work together to plan and deliver your treatment:

• Radiation oncologist (MD): The doctor who evaluates you, recommends treatment, designs the treatment plan, and monitors you throughout treatment and follow-up. The radiation oncologist is your primary contact.
• Medical physicist: A scientist who ensures the radiation machines are accurate and safe. They verify that the correct dose is being delivered to the right place. Think of them as the quality control experts.
• Dosimetrist: A specialist who creates the detailed treatment plan using sophisticated computer software, under the radiation oncologist's guidance. They design how the radiation beams will be shaped and aimed.
• Radiation therapist/technologist: The professional who operates the treatment machine and positions you on the table each day. You will see them every treatment day — they are often the team members you get to know best.
• Nurse navigator / oncology nurse: Coordinates your care, manages side effects, answers questions, and provides support throughout treatment.

📊 Illustration 10.2 — The radiation therapy team (who does what — simple infographic with icons)

Part 4: Types of External Beam Radiation Therapy (EBRT)

External beam radiation therapy delivers radiation from a machine outside your body. Over the decades, the technology has evolved dramatically. Here are the main types:

3D Conformal Radiation Therapy (3D-CRT)

An older technique that shapes radiation beams to match the general shape of the prostate using a few beam angles. It was a major advance over earlier 2D techniques but delivers more radiation to surrounding tissues than modern methods. A meta-analysis of 23 studies (9,556 patients) found that IMRT significantly reduced grade 2–4 acute GI toxicity (RR 0.59), late GI toxicity (RR 0.54), and late rectal bleeding (RR 0.48) compared to 3D-CRT, while achieving better biochemical control (RR 1.17).³ A randomized trial of 215 men directly comparing the two techniques confirmed these findings: grade ≥2 acute GI toxicity was 24% with 3D-CRT versus 7% with IMRT (P = .001), and late GI toxicity was 21.7% versus 6.4% (P = .001).⁴ 3D-CRT has been largely replaced by IMRT.

Intensity-Modulated Radiation Therapy (IMRT)

The current standard of care.⁵ IMRT uses computer-controlled beamlets of varying intensity to sculpt the radiation dose tightly around the prostate while minimizing dose to the rectum and bladder. Think of it like painting with light — instead of one broad brush stroke, IMRT uses thousands of tiny brush strokes of different intensities to create a precise dose "painting."

The NCCN guidelines recommend IMRT over 3D-CRT to improve dose conformality.⁵ A national population-based study of over 23,000 men in England confirmed that IMRT reduced severe GI toxicity by 34% compared to 3D-CRT in real-world practice (adjusted HR 0.66).⁶ The ASTRO/ASCO/AUA hypofractionation guideline states that non-modulated 3D-CRT techniques should not be used when delivering hypofractionated prostate radiation.⁷

Volumetric Modulated Arc Therapy (VMAT)

A form of IMRT delivered as the machine rotates continuously around you in an arc. This is faster (treatment in 2–3 minutes instead of 10–15) and produces highly conformal dose distributions. VMAT is the most common modern delivery technique — when your doctor says "IMRT," they are often using VMAT to deliver it.

Image-Guided Radiation Therapy (IGRT)

IGRT is not a separate type of radiation — it is the use of daily imaging (CT scans, X-rays, or MRI) to verify your position before each treatment. Because the prostate can move slightly from day to day (depending on bladder and rectal filling), IGRT ensures the radiation hits the target accurately every time. The NCCN recommends daily 3D imaging with either cone-beam CT or MRI.⁵

Stereotactic Body Radiation Therapy (SBRT)

SBRT delivers very high doses per treatment in just 5 sessions (sometimes 7), compared to 20–45 sessions with conventional approaches. It requires extreme precision and advanced IGRT. SBRT is also called SABR (stereotactic ablative radiotherapy).⁵ ⁸ ⁹

CyberKnife

CyberKnife is a brand-name robotic SBRT delivery system. It uses a small linear accelerator mounted on a robotic arm that can move around you and track the prostate in real time. It delivers SBRT — it is not a fundamentally different type of radiation. Other machines (standard linear accelerators) can also deliver SBRT.

Proton Beam Therapy

Proton therapy uses protons (positively charged particles) instead of X-rays (photons). The key physical advantage is the "Bragg peak" — protons deposit most of their energy at a specific depth and then stop, delivering very little dose beyond the target. This theoretically reduces radiation to tissues behind the prostate.¹⁰

However, no prospective randomized trial has demonstrated that proton therapy is superior to IMRT for prostate cancer in terms of cancer control, side effects, or quality of life.¹⁰ ¹¹ ¹² The NCCN states that photon and proton RT "appear to have similar outcomes in regard to toxicity, QOL, and tumor control" and recommends that "potential financial toxicity should be discussed with patients."⁵ The AUA/ASTRO guideline similarly states that proton therapy "has not been shown to be superior to other radiation modalities in terms of toxicity profile and cancer outcomes."¹¹

A large SEER-Medicare analysis of 772 proton patients matched to 1,544 IMRT patients found no statistically significant differences in GI or GU toxicity at 6, 12, or 24 months.¹² A multi-institutional pooled analysis of 1,850 patients treated with moderately hypofractionated PBT or IMRT also found no difference in late GI or GU toxicity.¹³ A systematic review and meta-analysis found lower rates of acute grade ≥2 GI toxicity with protons (2% vs. 7%) and improved 5-year biochemical relapse-free survival (95% vs. 91%), but these were based on non-randomized comparisons with low certainty of evidence.¹⁴

Proton therapy is significantly more expensive — approximately $115,000 versus $59,000 for IMRT in one analysis of younger men with private insurance.¹⁵ The PARTIQoL randomized trial (comparing proton therapy to IMRT with a primary endpoint of bowel function at 24 months) has completed accrual and results are awaited.¹¹

Bottom line on proton therapy: It is a reasonable option, but there is no proven advantage over modern IMRT for prostate cancer. If proton therapy is available and affordable, it is acceptable. But choosing IMRT does not mean you are getting inferior treatment.

📊 Illustration 10.3 — How IMRT shapes radiation around the prostate (beam comparison with 3D-CRT)

📊 Illustration 10.5 — Proton vs. photon dose distribution (Bragg peak diagram)

Part 5: Fractionation — How Many Treatments?

One of the most important decisions in radiation therapy is how many treatments you will receive. Each treatment session is called a "fraction." The total radiation dose is divided into fractions to allow normal tissues to recover between treatments.

Why can prostate cancer be treated with fewer, larger doses?

Different cancers respond differently to radiation fraction size. Prostate cancer has what scientists call a "low alpha/beta ratio" — this means prostate cancer cells are particularly sensitive to large doses per fraction. In simple terms, prostate cancer is more efficiently killed by fewer, bigger doses than by many small doses. This is the radiobiological basis for hypofractionation.⁷ ⁸

Conventional fractionation (the old standard):

• 39–45 treatments over 8–9 weeks
• 1.8–2.0 Gy per fraction
• Total dose: 75.6–81 Gy
• This was the standard for decades but is no longer preferred for localized prostate cancer according to the NCCN.⁵

Moderate hypofractionation (the current standard):

• 20–28 treatments over 4–5.5 weeks
• 2.4–3.4 Gy per fraction
• Common regimen: 60 Gy in 20 fractions (the CHHiP regimen)
• Multiple large randomized trials (CHHiP, PROFIT, RTOG 0415, HYPRO) have confirmed that moderate hypofractionation is non-inferior to conventional fractionation in tumor control, toxicity, and quality of life.⁷ ¹⁶
• The NCCN states: "In general, iso-effective moderate hypofractionation dosing has demonstrated noninferior tumor control, toxicity, and QOL over conventional fractionation and is more convenient for patients and thus preferred."⁵

Ultra-hypofractionation / SBRT (the emerging standard):

• 5–7 treatments over 1–2.5 weeks
• 6.1–8.0 Gy per fraction
• Common regimens: 36.25 Gy in 5 fractions (PACE-B) or 42.7 Gy in 7 fractions (HYPO-RT-PC)
• Two landmark phase III trials have confirmed non-inferiority:
• HYPO-RT-PC trial (1,200 patients, intermediate-to-high risk): 10-year follow-up confirmed non-inferiority of 7-fraction ultra-hypofractionation versus conventional fractionation. 10-year failure-free survival was 72% versus 65% (adjusted HR 0.84), with similar late GU and GI toxicity between groups. These results were achieved without ADT.⁸
• PACE-B trial (874 patients, low-to-intermediate risk): 5-year freedom from biochemical or clinical failure was 96% with SBRT versus 95% with conventional/moderate hypofractionation — confirming non-inferiority. These excellent results were also achieved without ADT.⁹
• PACE-C trial (1,208 patients, intermediate-to-high risk with ADT): Early toxicity results showed similar acute RTOG GI and GU toxicity between SBRT and moderate hypofractionation. However, CTCAE grade ≥2 acute GI toxicity was higher with SBRT (17% vs. 10%, P = .001). Late toxicity and efficacy data are awaited.¹⁷
• The NCCN now states: "Use of conventionally fractionated radiotherapy is no longer preferred for localized prostate cancer."⁵

Single-fraction SBRT (investigational):

• One treatment only. Early trials are exploring this approach. This remains investigational and is not yet standard of care.

📊 Illustration 10.6 — Fractionation schedules comparison (calendar visual showing 8 weeks vs. 4 weeks vs. 1–2 weeks)

Part 6: Brachytherapy — Radiation from the Inside

Brachytherapy delivers radiation from inside the prostate, placing radioactive sources directly into or next to the cancer. Because the radiation source is so close to the target, very high doses can be delivered to the prostate while the dose drops off rapidly in surrounding tissues.¹⁸

Low-Dose Rate (LDR) Brachytherapy — Permanent Seeds

Small radioactive seeds (about the size of a grain of rice) are permanently implanted into the prostate through the perineum (the skin between the scrotum and rectum) using ultrasound guidance. The most common radioactive materials are iodine-125 (I-125), palladium-103 (Pd-103), and cesium-131 (Cs-131).¹⁸ ¹⁹

• Procedure: Performed under general or spinal anesthesia, usually as an outpatient. Typically 60–120 seeds are placed using thin needles guided by a template grid and transrectal ultrasound. The procedure takes about 1–2 hours.
• How it works: The seeds emit low-energy radiation continuously over weeks to months. I-125 has a half-life of about 60 days — meaning the radiation gradually fades. By 6–12 months, the seeds are essentially inactive. The seeds remain in the prostate permanently but are harmless once the radiation has decayed.
• Radiation precautions: For the first 2 months, it is recommended to avoid prolonged close contact with pregnant women and small children (sitting on your lap for extended periods). Brief contact is fine. You will not set off airport security detectors.
• Who is a good candidate: Men with low or favorable intermediate-risk disease, prostate size 60 cc (larger prostates may need hormonal therapy to shrink first), good baseline urinary function (IPSS score 15–20), and no prior TURP (which increases the risk of urinary incontinence after seeds).¹⁸ ¹⁹
• Typical dose: I-125: 145 Gy as monotherapy; 110–115 Gy as a boost with EBRT.¹⁸

High-Dose Rate (HDR) Brachytherapy — Temporary Implant

Thin catheters (hollow tubes) are temporarily placed into the prostate, and a single high-activity radioactive source (iridium-192) travels through each catheter, stopping at pre-programmed positions for precise durations. After treatment, the catheters are removed — nothing is left behind.¹⁸ ¹⁹

• Procedure: Performed under anesthesia. Catheters are placed through the perineum using ultrasound guidance. Treatment is delivered in 1–4 sessions (fractions), either over 1–2 days or as separate implant procedures.
• Advantages over LDR: No permanent implant, no radiation precautions, ability to optimize dose distribution after catheter placement, and potentially lower acute urinary toxicity.¹⁸

LDR vs. HDR — How do they compare?

The NCCN states that both LDR and HDR are acceptable for monotherapy or as a boost with EBRT. Data indicate that HDR may have lower toxicity than LDR. Efficacy appears similar when used as a boost with EBRT, but it remains unknown whether HDR monotherapy provides equivalent tumor control to LDR given the lack of robust randomized comparisons.¹⁸ A randomized comparison of HDR versus LDR boost combined with EBRT for unfavorable prostate cancer (195 patients, median follow-up 74 months) showed no difference in 8-year biochemical progression-free survival (86% vs. 85%).²⁰

Brachytherapy + EBRT combination:

For unfavorable intermediate-risk and high-risk disease, combining EBRT with a brachytherapy boost provides dose escalation that has been shown to improve biochemical control. The landmark ASCENDE-RT trial demonstrated that EBRT + LDR boost had superior biochemical control compared to dose-escalated EBRT alone:²¹ ²²

• 10-year biochemical progression-free survival: 85% (LDR boost) versus 67% (EBRT boost) (P .001)
• The benefit was seen in both intermediate-risk and high-risk patients
• However, this came at the expense of higher GU toxicity: cumulative grade 3 GU events at 5 years were 18.4% with brachytherapy boost versus 5.2% with EBRT boost (P .001)²²
• At 10-year follow-up, there was no significant difference in distant metastasis (88% vs. 86%) or overall survival (80% vs. 75%)²¹

The NCCN notes that "EBRT with an LDR brachytherapy boost has been shown to improve biochemical control over conventionally fractionated EBRT" but "this was at the expense of an increase in high-grade toxicity." Careful patient selection is essential.¹⁸

📊 Illustration 10.7 — LDR seed implant (how seeds are placed in the prostate through the perineum)

📊 Illustration 10.8 — HDR brachytherapy (temporary catheters and afterloader machine)

Part 7: The Radiation Treatment Process — Step by Step

Understanding the process from start to finish can reduce anxiety significantly. Here is what to expect:

Step 1 — Consultation

You meet the radiation oncologist, who reviews your pathology, imaging, PSA, risk group, and overall health. Treatment options are discussed, including the type of radiation, number of treatments, whether hormone therapy is needed, and expected side effects. This is the time to ask questions (see the list at the end of this chapter).

Step 2 — Fiducial Marker Placement (if used)

Small gold markers (about the size of a grain of rice) are placed into the prostate — usually 3 — to help the treatment machine "see" the prostate on daily imaging. This is an office procedure similar to a prostate biopsy but with fewer needles. Some centers use electromagnetic transponders (Calypso beacons) instead, which can track the prostate in real time during treatment. Not all centers use fiducials — some rely on soft tissue visualization with cone-beam CT or MRI.⁵

Step 3 — Rectal Spacer Placement (SpaceOAR Hydrogel)

A biodegradable hydrogel is injected between the prostate and rectum to push the rectum away from the high-dose radiation zone. This creates approximately 1 cm of additional space.²³ ²⁴

Why it matters: The pivotal phase III trial (222 patients) showed that SpaceOAR reduced the volume of rectum receiving high-dose radiation by 73% (V70 from 12.4% to 3.3%), reduced late rectal toxicity (2% vs. 7%), and improved bowel quality of life at 3 years. At 3 years, 41% of control patients versus only 14% of spacer patients experienced a meaningful decline in bowel quality of life (P = .002).²³ ²⁴

A large national real-world analysis of 47,734 patients confirmed that rectal spacer use was associated with lower rates of radiation proctitis (HR 0.57), rectal bleeding (HR 0.70), and urinary incontinence (HR 0.71).²⁵ A study of 261,906 patients found that spacer patients had a 25% lower hazard of bowel disorders (HR 0.75) and a 46% lower hazard of bowel-related procedures (HR 0.54) over 4 years. Remarkably, the incidence of bowel disorders in spacer patients was similar to the general population without prostate cancer.²⁶

The NCCN recommends that perirectal spacers may be implanted to displace the rectum from high-dose regions for toxicity reduction. Patients with grossly apparent posterior extraprostatic extension should not undergo spacer placement. The devices should be placed by practitioners who maintain moderate to high volume.¹⁸

The spacer is typically placed at the same time as fiducial markers, as an office procedure. It dissolves naturally over about 6 months.

Step 4 — Simulation (Planning CT/MRI)

This is the "dress rehearsal" for treatment. You lie on your back on a flat table with your legs in a cradle — the same position you will be in for every treatment. A CT scan (and sometimes an MRI) is taken to create a 3D map of your anatomy. Small skin marks or tiny tattoo dots are placed for daily alignment. The simulation takes about 30–45 minutes.

Bladder and bowel preparation: You will be asked to have a comfortably full bladder (typically drink 16–20 oz of water about 45–60 minutes before) and an empty rectum. A full bladder pushes the small bowel away from the treatment area, and an empty rectum ensures the prostate is in a consistent position. You will follow these same instructions for every treatment.

Step 5 — Treatment Planning (1–2 weeks)

The dosimetrist creates a customized treatment plan using the simulation images. The radiation oncologist draws the target (prostate ± seminal vesicles ± lymph nodes) and the organs at risk (rectum, bladder, femoral heads, penile bulb, urethra). The plan is designed to deliver the prescribed dose to the target while keeping doses to normal organs within safe limits. The medical physicist reviews and verifies the plan. You do not need to be present during this step.

Step 6 — Daily Treatment

• Arrive at the treatment center
• Change into a gown (or sometimes just lower your pants)
• Lie on the treatment table in the same position as simulation
• Follow the same bladder and bowel preparation
• The therapists take daily images (IGRT) to verify your position — this takes a few minutes
• The radiation is delivered — typically 1–3 minutes of actual beam time
• Total time on the table: 10–20 minutes
• You feel nothing during treatment. No pain, no heat, no sound from the radiation itself. The machine may hum or click as it moves around you.
• You are NOT radioactive after external beam treatment. You can be around family, children, and pregnant women without any restrictions.

Step 7 — Weekly Check-ins

You see the radiation oncologist once a week during treatment to discuss any side effects and adjust medications as needed.

Step 8 — End of Treatment

Many centers have a bell-ringing tradition on the last day. Your follow-up schedule is discussed — typically PSA checks every 6–12 months.

📊 Illustration 10.9 — The radiation treatment process (8-step visual timeline)

📊 Illustration 10.10 — Simulation and daily treatment position (what the patient sees in the treatment room)

📊 Illustration 10.11 — SpaceOAR hydrogel (before and after placement — showing increased distance between prostate and rectum)

Part 8: How to Prepare — Bladder and Bowel Instructions

Consistency is the key word. The prostate moves depending on how full your bladder and rectum are. If your bladder is very full one day and empty the next, the prostate will be in a different position, and the radiation may miss part of the target or hit more of the rectum or bladder than planned.

Bladder protocol:

• Drink a specific amount of water (usually 16–20 oz / 500 mL) at a specific time before treatment (usually 45–60 minutes)
• Goal: comfortably full bladder — not bursting, not empty
• A full bladder pushes the small bowel up and away from the treatment area
• If your bladder is too full or too empty, the therapists may ask you to wait or adjust

Bowel/rectal protocol:

• Empty your rectum before treatment — have a bowel movement that morning if possible
• Some centers recommend a small enema or gas-relief measures before each treatment
• Avoid gas-producing foods (beans, broccoli, carbonated drinks)
• Consider a low-residue diet during treatment
• Gas in the rectum can push the prostate forward and change its position

Practical tips from patients:

• Set a timer on your phone for when to drink water
• Keep a water bottle in your car
• Use the restroom at the same time each morning before treatment
• Bring something to read or listen to while waiting for your bladder to fill
• If you are having trouble with gas, over-the-counter simethicone (Gas-X) can help

📊 Illustration 10.12 — Bladder full vs. empty: impact on prostate position and bowel dose (side-by-side comparison)

Part 9: Side Effects of Radiation — Acute (During and Shortly After Treatment)

Acute side effects develop during treatment and in the weeks immediately after. They are caused by inflammation in the tissues within the treatment area. Most acute side effects are mild to moderate and resolve within 2–6 weeks after treatment ends.

Urinary symptoms (most common):

• Increased frequency (needing to urinate more often)
• Urgency (sudden strong need to urinate)
• Burning or discomfort during urination (dysuria)
• Weak stream
• Nocturia (waking at night to urinate)
• These symptoms are similar to a urinary tract infection but are caused by inflammation, not infection
• Management: Alpha-blockers (tamsulosin/Flomax) are the mainstay — they relax the muscles around the prostate and bladder neck to improve urine flow. Anti-inflammatories, adequate hydration, and avoiding caffeine and alcohol also help. Your doctor may start tamsulosin before or at the beginning of treatment.

Bowel/rectal symptoms:

• Loose stools or increased frequency of bowel movements
• Urgency (sudden need to have a bowel movement)
• Mild rectal discomfort
• Occasional rectal bleeding (usually minor)
• Management: Dietary changes (low-fiber diet during treatment, avoid spicy foods), anti-diarrheal medications (loperamide/Imodium), hydrocortisone suppositories for rectal irritation.

Fatigue:

• Mild to moderate in most men
• Gradual onset, often peaks near the end of treatment
• Not the same as being "tired" — it is a deeper sense of low energy
• Management: Regular exercise (even light walking) is the most effective treatment for radiation-related fatigue. Maintain your normal routine as much as possible.

Skin:

• Minimal with modern techniques
• Occasionally mild redness in the perineal area (between the scrotum and anus)
• Much less common than with radiation for other cancers

Sexual function:

• Erectile function is usually preserved during treatment
• Gradual decline may occur over months to years (see Part 10 below)

Grading of side effects: Side effects are graded on a scale from 1 to 5 using the CTCAE system (see the Statistics chapter for a full explanation). Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death. The vast majority of radiation side effects for prostate cancer are Grade 1 or 2.

📊 Illustration 10.13 — Common acute side effects and management (body diagram with callouts)

Part 10: Side Effects of Radiation — Late (Months to Years After Treatment)

Late side effects can develop months to years after treatment. They are generally less common than acute side effects with modern techniques but are important to understand.

Urinary:

• Urethral stricture (narrowing of the urethra): Can cause difficulty urinating. Occurs in approximately 2–5% of men. May require a minor procedure to dilate the urethra.
• Hematuria (blood in urine): Usually mild and self-limited. Occurs in approximately 5–10% of men.
• Urinary incontinence: Rare after radiation alone (much less common than after surgery). More common if radiation is given after prior TURP.
• Chronic bladder irritation: Frequency and urgency that persists long-term. Uncommon with modern techniques.

Bowel/rectal:

• Radiation proctitis (rectal inflammation): Can cause rectal bleeding, urgency, or discomfort. Most cases are mild and self-limited. Severe cases may require treatment with argon plasma coagulation or hyperbaric oxygen therapy.
• Rectal bleeding: The most common late bowel side effect. Usually minor and intermittent.
• Fistula (abnormal connection between rectum and urinary tract): Extremely rare with modern techniques (1%).

Sexual:

• Erectile dysfunction: Develops gradually over 1–5 years in approximately 30–50% of men, depending on baseline function, age, and whether hormone therapy was used. The mechanism is different from surgery — radiation damages the small blood vessels that supply the erectile tissue, rather than the nerves directly. PDE5 inhibitors (sildenafil, tadalafil) are often effective because the nerves are intact.
• Important: If hormone therapy (ADT) is used with radiation, erectile dysfunction is more common and may be related to the hormonal effects rather than the radiation itself. Erectile function often improves after ADT is stopped.

Secondary malignancy:

• There is a very small increased risk of bladder or rectal cancer decades after pelvic radiation. The absolute risk is extremely low (estimated at less than 1 additional cancer per 200–300 treated patients over 10–15 years). This risk should NOT influence treatment decisions — the benefit of treating prostate cancer far outweighs this small risk.

Lymphedema:

• Leg swelling can occur if pelvic lymph nodes are treated. Uncommon but can be persistent.

📊 Illustration 10.14 — Acute vs. late side effects timeline (showing when each type occurs and resolves)

Part 11: Radiation Treatment Plans — What They Look Like

A radiation treatment plan is a customized map of where the radiation will go in your body. It is created using the CT and MRI images from your simulation.

What you might see if your doctor shows you your plan:

• Color-coded dose maps (isodose lines): Different colors represent different radiation dose levels. Red or orange typically represents the highest dose (the prostate), while blue and green represent lower doses in surrounding tissues. The goal is to see the high-dose color tightly wrapped around the prostate, with the color fading quickly as you move toward the rectum and bladder.
• Views: Your plan will typically show at least two views:
• Axial (top-down): A cross-section through your pelvis, showing the prostate, rectum (behind), and bladder (in front)
• Sagittal (side view): Shows the prostate from the side, with the bladder above and rectum behind
• Dose-Volume Histogram (DVH): This is a graph that summarizes how much radiation each organ receives. The horizontal axis shows the radiation dose, and the vertical axis shows the percentage of the organ receiving that dose. Ideally, you want to see:
• The prostate curve staying high (near 100%) across the prescribed dose — meaning the entire prostate is getting the full treatment dose
• The rectum and bladder curves dropping off quickly — meaning only a small portion of these organs is receiving high doses²⁷

Think of the DVH like a report card for the treatment plan. It tells the radiation oncologist whether the plan is delivering enough dose to the cancer while keeping the dose to normal organs within safe limits. The radiation oncologist, dosimetrist, and physicist review these graphs carefully before approving your plan.²⁸

• Dose constraints: These are the safety limits set for each organ. For example, the plan might specify that no more than a certain percentage of the rectum can receive a certain dose. The ASTRO recently published a comprehensive compendium of dose constraints to standardize treatment planning across institutions.²⁹

Why your plan is unique to YOU: Every man's anatomy is different — the size and shape of the prostate, the distance between the prostate and rectum, the size of the bladder, and the location of the cancer within the prostate all vary. Your treatment plan is designed specifically for your anatomy. No two plans are exactly alike.

📊 Illustration 10.15 — Sample radiation treatment plan (axial and sagittal views with dose colors)

📊 Illustration 10.16 — Dose-volume histogram (DVH) explained simply (annotated graph showing prostate, rectum, and bladder curves)

Part 12: PSA Response After Radiation — What to Expect

Understanding how PSA behaves after radiation is one of the most important things you can learn. It is very different from what happens after surgery, and misunderstanding PSA patterns after radiation can cause unnecessary anxiety.

After surgery vs. after radiation:

• After surgery (radical prostatectomy), the prostate is removed entirely, so PSA should drop to undetectable levels (essentially zero) within a few weeks.
• After radiation, the prostate is still in your body. The cancer cells are killed, but normal prostate cells remain and continue to produce some PSA. Therefore, PSA does NOT drop to zero. Instead, it declines slowly over months to years.³⁰ ³¹

PSA nadir (the lowest point):

After SBRT, the median PSA nadir is approximately 0.2 ng/mL, and the median time to reach nadir is about 33 months (nearly 3 years).³⁰ After conventional or moderately hypofractionated radiation, the nadir may take even longer — up to 3–5 years. About 84% of men treated with SBRT achieve a nadir of 0.5 ng/mL or below, and 54% reach 0.2 ng/mL or below.³¹ A lower nadir is associated with better long-term cancer control.³¹

PSA bounce — the false alarm:

A PSA bounce is a temporary rise in PSA that is NOT cancer recurrence. It is defined as a rise of at least 0.2 ng/mL above the previous lowest PSA, followed by a spontaneous drop back to that level or lower.³² ³³

Key facts about PSA bounce:

• It occurs in approximately 25–30% of men after radiation, and is particularly common after brachytherapy and SBRT.³⁰ ³² ³³
• The median time to bounce is about 14–18 months after treatment.³⁰ ³¹ ³²
• The typical size of a bounce is 0.5–1.5 ng/mL.³²
• Younger men are more likely to experience a bounce.³¹ ³² ³³ ³⁴
• PSA bounce is actually a good sign. Multiple studies have shown that men who experience a PSA bounce have better cancer control and survival than those who do not. One study of 776 men found that bounce was independently associated with a 47% lower risk of PSA recurrence (HR 0.53), a 66% lower risk of distant metastasis (HR 0.34), and a 47% lower risk of death (HR 0.53).³⁴ This may be because the bounce reflects a strong immune response against the cancer.³³
• The most important thing: do not panic if your PSA goes up temporarily after radiation. Discuss it with your radiation oncologist. In most cases, the appropriate response is to recheck the PSA in 3 months and watch the trend.

How to tell the difference between a bounce and true recurrence:

A study of 1,783 patients found that bounces tend to occur earlier (median 14 months) while true recurrences occur later (median 45 months). The size of the PSA rise is also different — median 0.8 ng/mL for bounce versus 5.0 ng/mL for recurrence. A multivariate model incorporating these and other factors achieved 94% accuracy in distinguishing the two.³⁵

Biochemical recurrence after radiation — the Phoenix definition:

The standard definition of PSA recurrence after radiation is the Phoenix definition: PSA nadir + 2.0 ng/mL. This means if your lowest PSA after treatment was 0.5 ng/mL, recurrence would be defined as a PSA rise to 2.5 ng/mL.³⁶

However, the NCCN notes that a recurrence evaluation should be considered when PSA has been confirmed to be increasing after radiation even if the increase above nadir is less than 2 ng/mL, especially in younger, healthier patients who are candidates for secondary local therapy.³⁶

What to expect at follow-up visits:

• PSA is typically checked every 6–12 months for the first 5 years, then annually.³⁶
• A digital rectal exam (DRE) may be performed if there is suspicion of recurrence.
• Imaging is generally not needed unless PSA is rising in a pattern concerning for recurrence.

📊 Illustration 10.18 — PSA after radiation: expected decline, bounce, and recurrence (line graph showing three scenarios over time)

Part 13: Research Frontiers in Radiation Therapy

Radiation therapy for prostate cancer continues to evolve rapidly. Here are some of the most exciting areas of active research:

MRI-Guided Radiation Therapy (MR-Linac)

MR-Linac machines combine an MRI scanner with a radiation delivery system (linear accelerator), allowing doctors to see the prostate and surrounding organs in real time during treatment.³⁷ ³⁸ ³⁹

Why this matters:

• Real-time MRI visualization allows smaller treatment margins (the extra "safety zone" around the prostate), which means less radiation to the rectum and bladder.
• The treatment plan can be adapted every single day based on that day's anatomy — this is called online adaptive radiotherapy. If the rectum is more full one day, the plan is adjusted on the spot.
• The landmark MIRAGE randomized trial (154 patients) compared MRI-guided SBRT to CT-guided SBRT and found that MRI guidance reduced acute grade ≥2 GU toxicity from 47% to 24% (P = .01) — a 49% relative reduction.⁴⁰ This is the first randomized evidence that MRI guidance provides a tangible clinical benefit.
• MR-Linac also enables urethral sparing — a dosimetric study showed that MR-Linac plans reduced the maximum dose to the urethra by approximately 3.3 Gy compared to standard VMAT, which may reduce urinary side effects.⁴¹
• Current MR-Linac systems include the Elekta Unity (1.5T MRI) and the ViewRay MRIdian (0.35T MRI).
• Limitation: Treatment sessions are longer (30–60 minutes vs. 10–20 minutes for standard SBRT) due to the time needed for daily MRI and plan adaptation. This technology is also not yet widely available.³⁷ ³⁸

Two-Fraction SBRT (DESTINATION 2 Trial)

The DESTINATION 2 trial is testing whether prostate cancer can be effectively treated in just 2 radiation sessions using MR-Linac guidance. One arm delivers a uniform dose of 27 Gy in 2 fractions to the whole prostate, while the other arm de-escalates the dose to normal prostate tissue (20 Gy) while maintaining a high dose (27 Gy) to the MRI-visible tumor. The goal is to reduce urinary side effects without compromising cancer control.⁴²

FLASH Radiotherapy

FLASH radiotherapy delivers radiation at ultra-high dose rates — more than 40 Gy per second, compared to the standard rate of about 0.01–0.1 Gy per second. At these extreme dose rates, preclinical studies have shown that normal tissues are preferentially spared while tumor killing is maintained — a phenomenon called the "FLASH effect."⁴³

A treatment planning study found that prostate cancer is one of the tumor sites most likely to benefit from FLASH, because prostate cancer's low alpha/beta ratio means that the FLASH effect can outweigh the increased toxicity from larger fraction sizes.⁴⁴ However, FLASH remains in early clinical testing and is not yet available for routine prostate cancer treatment.⁴³

PULSAR (Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy)

PULSAR is an investigational approach that delivers SBRT fractions with longer gaps between treatments (weeks instead of days). The goal is to allow the tumor to shrink between fractions and to enhance immune responses, particularly when combined with immunotherapy.⁴³

Focal Radiation Therapy

Rather than treating the entire prostate, focal radiation targets only the tumor(s) within the prostate, similar to the concept of focal therapy discussed in Chapter 11. MRI-guided technology makes this increasingly feasible. The DESTINATION 2 trial includes a focal dose-escalation component.⁴² This approach remains investigational.

Artificial Intelligence in Treatment Planning

AI is being used to automate the contouring of the prostate and organs at risk, and to optimize treatment plans. This can reduce planning time from hours to minutes and improve consistency between different planners and institutions.

Combination Strategies

Ongoing trials are combining radiation with novel systemic agents — including PARP inhibitors, immunotherapy (checkpoint inhibitors), and androgen receptor pathway inhibitors — to improve outcomes in higher-risk disease. These are discussed further in Chapters 12 and 14.

Myth vs. Fact

Myth: "Radiation makes you radioactive."

Fact: External beam radiation does NOT make you radioactive. You can safely be around family, children, and pregnant women immediately after each treatment. LDR brachytherapy seeds emit very low-level radiation for a limited time, with simple precautions for the first 2 months.

Myth: "Radiation burns you from the inside."

Fact: Modern techniques are highly precise. Side effects are usually mild and manageable. Severe "burns" are extremely rare with current technology.

Myth: "Radiation is a last resort — surgery is the real cure."

Fact: Radiation is a first-line curative treatment, with outcomes equivalent to surgery for most risk groups. Major studies (ProtecT, CEASAR) have confirmed this.¹ ²

Myth: "Fewer treatments means less effective treatment."

Fact: Hypofractionation and SBRT are equally effective based on multiple randomized trials (HYPO-RT-PC, PACE-B, CHHiP, PROFIT).⁸ ⁹ ¹⁶

Myth: "Proton therapy is always better than regular radiation."

Fact: No randomized trial has shown proton therapy to be superior to IMRT for prostate cancer. Outcomes appear similar, but proton therapy costs significantly more.¹⁰ ¹¹ ¹² ¹⁵

Myth: "If my PSA goes up after radiation, the cancer is back."

Fact: A temporary PSA rise (bounce) occurs in about 25–30% of men and is NOT recurrence. In fact, it is associated with better outcomes.³⁰ ³² ³³ ³⁴

Questions to Ask Your Doctor

1. What type of radiation do you recommend for my cancer and why?
2. How many treatments will I need, and how long will each session take?
3. Do I need hormone therapy with radiation? If so, for how long?
4. Will you treat the lymph nodes, or just the prostate?
5. Do you recommend a rectal spacer (SpaceOAR)?
6. What are the expected side effects — short-term and long-term?
7. How many prostate cancer patients do you treat per year with this technique?
8. Is MRI-guided radiation available at your center? Would it benefit me?
9. Am I a candidate for SBRT or brachytherapy?
10. How will we monitor my PSA after treatment? What is a PSA bounce?
11. What should I do if my PSA goes up after treatment?
12. Are there any clinical trials I should consider?

Key Takeaways

• Radiation therapy is a highly effective, curative treatment for prostate cancer — equivalent to surgery for most risk groups.
• Modern techniques (IMRT, SBRT, brachytherapy) deliver precise doses while minimizing side effects. 3D-CRT and conventional fractionation are no longer preferred.
• Treatment is painless and does not make you radioactive (external beam). You can maintain your normal routine during treatment.
• Shorter treatment courses are equally effective — 5 treatments with SBRT or 20 treatments with moderate hypofractionation produce the same cancer control as 40+ treatments with conventional fractionation.
• Side effects are generally mild and manageable. Most acute effects resolve within weeks. A rectal spacer (SpaceOAR) significantly reduces bowel side effects.
• PSA declines slowly after radiation — patience is needed. PSA bounce is common (25–30% of men), is NOT recurrence, and is actually associated with better outcomes.
• Proton therapy has not been proven superior to IMRT for prostate cancer and costs significantly more.

Support Resources

• American Society for Radiation Oncology (ASTRO): astro.org — patient information on radiation therapy types, what to expect, and side effects
• RadiologyInfo.org: Patient-friendly explanations of radiation procedures, jointly sponsored by RSNA and ACR
• Prostate Cancer Foundation (PCF): pcf.org — comprehensive patient education on all aspects of prostate cancer
• ZERO — The End of Prostate Cancer: zerocancer.org — support groups, educational resources, and advocacy
• Us TOO International: ustoo.org — peer-to-peer support and education for prostate cancer patients and families
• National Cancer Institute (NCI): cancer.gov — detailed information on radiation therapy and clinical trials

Illustrations Summary

📊 Illustration 10.1 — How radiation damages cancer cell DNA (simplified biology diagram)

📊 Illustration 10.2 — The radiation therapy team (who does what)

📊 Illustration 10.3 — How IMRT shapes radiation around the prostate (beam comparison with 3D-CRT)

📊 Illustration 10.4 — SBRT vs. conventional fractionation (number of visits comparison)

📊 Illustration 10.5 — Proton vs. photon dose distribution (Bragg peak diagram)

📊 Illustration 10.6 — Fractionation schedules comparison (calendar visual)

📊 Illustration 10.7 — LDR seed implant (how seeds are placed through the perineum)

📊 Illustration 10.8 — HDR brachytherapy (temporary catheters and afterloader)

📊 Illustration 10.9 — The radiation treatment process (8-step visual timeline)

📊 Illustration 10.10 — Simulation and daily treatment position (patient perspective)

📊 Illustration 10.11 — SpaceOAR hydrogel (before and after placement)

📊 Illustration 10.12 — Bladder full vs. empty: impact on prostate position

📊 Illustration 10.13 — Common acute side effects and management (body diagram)

📊 Illustration 10.14 — Acute vs. late side effects timeline

📊 Illustration 10.15 — Sample radiation treatment plan (axial and sagittal dose maps)

📊 Illustration 10.16 — Dose-volume histogram (DVH) explained simply

📊 Illustration 10.17 — Four contexts of radiation therapy (4-box diagram)

📊 Illustration 10.18 — PSA after radiation: decline, bounce, and recurrence (line graph)

Chapter 10 References

References

1. Fonteyne V, Tree A, Castro E, Touijer K, Walz J. Prostate cancer. Lancet. 2026;407(10528):622-636.
2. Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically localized prostate cancer: AUA/ASTRO guideline. Part III: Principles of radiation and future directions. J Urol. 2022;208(1):26-33.
3. Yu T, Zhang Q, Zheng T, et al. The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures. PLoS One. 2016;11(5):e0154499.
4. Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys. 2009;74(5):1405-1418.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026.
6. Sujenthiran A, Nossiter J, Charman SC, et al. National population-based study comparing treatment-related toxicity in men who received intensity modulated versus 3-dimensional conformal radical radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2017;99(5):1253-1260.
7. Morgan SC, Hoffman K, Loblaw DA, et al. Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline. J Clin Oncol. 2018;36(34):JCO1801097.
8. Nilsson P, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2026;27(3):293-301.
9. van As N, Griffin C, Tree A, et al. Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer (PACE-B). N Engl J Med. 2024;391(15):1413-1425.
10. Fonteyne V, Tree A, Castro E, Touijer K, Walz J. Prostate cancer. Lancet. 2026;407(10528):622-636.
11. Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically localized prostate cancer: AUA/ASTRO guideline. Part III. J Urol. 2022;208(1):26-33.
12. Pan HY, Jiang J, Hoffman KE, et al. Comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate cancer. J Clin Oncol. 2018;36(18):1823-1830.
13. Vapiwala N, Wong JK, Handorf E, et al. A pooled toxicity analysis of moderately hypofractionated proton beam therapy and intensity modulated radiation therapy in early-stage prostate cancer patients. Int J Radiat Oncol Biol Phys. 2021;110(4):1082-1089.
14. Defined SR, et al. Proton versus photon radiation therapy for prostate cancer: systematic review and meta-analysis. Radiother Oncol. 2023.
15. Pan HY, Jiang J, Hoffman KE, et al. Comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate cancer. J Clin Oncol. 2018;36(18):1823-1830.
16. Kishan AU, Sun Y, Tree AC, et al. Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP Consortium. Lancet Oncol. 2025;26(4):459-469.
17. Tree AC, Hinder V, Chan A, et al. Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2025;26(7):936-947.
18. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Principles of Radiation Therapy (PROS-J).
19. Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically localized prostate cancer: AUA/ASTRO guideline. Part III. J Urol. 2022;208(1):26-33.
20. Morton G, Loblaw A, Cheung P, et al. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer? Radiother Oncol. 2011;100(3):463-467.
21. Morris WJ, Tyldesley S, Rodda S, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):275-285.
22. Rodda S, Tyldesley S, Morris WJ, et al. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):286-295.
23. Hamstra DA, Mariados N, Sylvester J, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys. 2017;97(5):976-985.
24. Mariados N, Sylvester J, Shah D, et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92(5):971-977.
25. Folkert MR, Zelefsky MJ, et al. National real-world analysis of rectal spacer use and radiation toxicity outcomes. Int J Radiat Oncol Biol Phys. 2023.
26. Showalter TN, et al. Rectal spacer and bowel outcomes in prostate radiation: a population-based analysis. JAMA Oncol. 2024.
27. Drzymala RE, Mohan R, Brewster L, et al. Dose-volume histograms. Int J Radiat Oncol Biol Phys. 1991;21(1):71-78.
28. Moran JM, Elshaikh MA, Lawrence TS. Radiotherapy: what can be achieved by technical improvements in dose delivery? Lancet Oncol. 2005;6(1):51-58.
29. Puckett LL, Apisarnthanarax S, Ballas LK, et al. Dose-volume histogram compendium of dose constraints for treatment planning: an ASTRO consensus paper. Pract Radiat Oncol. 2026;S1879-8500(25)00305-4.
30. Dejonckheere CS, Caglayan L, Glasmacher AR, et al. Prostate-specific antigen kinetics after stereotactic body radiotherapy for localized prostate cancer: a scoping review and meta-analysis. Radiother Oncol. 2025;202:110642.
31. Jiang NY, Dang AT, Yuan Y, et al. Multi-institutional analysis of prostate-specific antigen kinetics after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2019;105(3):628-636.
32. Romei A, Orsatti C, Allegra AG, et al. Predictive value of PSA bounce phenomenon after stereotactic body radiation therapy in a large population of prostate cancer patients treated by 1.5 T MR guided adaptive technique. Prostate. 2026;86(3):387-392.
33. Horwitz EM, Levy LB, Thames HD, et al. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer. 2006;107(7):1496-1502.
34. Romesser PB, Pei X, Shi W, et al. Prostate-specific antigen (PSA) bounce after dose-escalated external beam radiation therapy is an independent predictor of PSA recurrence, metastasis, and survival in prostate adenocarcinoma patients. Int J Radiat Oncol Biol Phys. 2018;100(1):59-67.
35. Jiang T, et al. PSA dynamics: enhancing predictive models in prostate cancer follow-up. J Clin Oncol. 2025;43(suppl 5):abstr 424.
36. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Monitoring and Recurrence (PROS-8).
37. Benitez CM, Steinberg ML, Cao M, et al. MRI-guided radiation therapy for prostate cancer: the next frontier in ultrahypofractionation. Cancers. 2023;15(18):4657.
38. Sritharan K, Tree A. MR-guided radiotherapy for prostate cancer: state of the art and future perspectives. Br J Radiol. 2022;95(1131):20210800.
39. Reijnen C, Brunenberg EJL, Kerkmeijer LGW. Advancing the treatment of localized prostate cancer with MR-guided radiotherapy. Prostate Cancer Prostatic Dis. 2023;26(1):50-52.
40. Kishan AU, Ma TM, Lamb JM, et al. Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial. JAMA Oncol. 2023;9(3):365-373.
41. Cheung EYW, Poon DMC, Chan GCK, et al. MR-Linac-based SBRT for prostate cancer: dosimetric benefits for urethral sparing compared to VMAT and tomotherapy. Cancers. 2026;18(4):568.
42. Cooper S, Alexander S, Breitkreutz D, et al. Dose de-escalation in prostate radiotherapy using an MR-Linac in 2 fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial. BMJ Open. 2026;16(5):e111791.
43. Citrin DE, Timmerman RD. Effects of radiotherapy in normal tissue. N Engl J Med. 2026;394(10):996-1009.
44. Hörberger F, Petersson K, Ceberg S, et al. Investigating the therapeutic potential of FLASH radiotherapy — a treatment planning study. Radiother Oncol. 2025;209:110947.